Home › Funds › Balyasny Asset Management › PCVX
Balyasny Asset Management position in PCVX
VAXCYTE INC · Health Care
Latest position (Q1 2026)514.58K sh
Reported value held$29.90M
Portfolio Weight0.04%
First reportedQ3 2022
Last changeAdd
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2022 | 9.42K | $226.00K | New |
| Q2 2023 | 284.00K | $14.18M | New |
| Q2 2024 | 418.71K | $31.62M | New |
| Q3 2024 | 74.17K | $8.48M | Reduce |
| Q1 2025 | 25.30K | $955.33K | New |
| Q2 2025 | 154.84K | $5.03M | Add |
| Q3 2025 | 278.13K | $10.02M | Add |
| Q4 2025 | 26.86K | $1.24M | Reduce |
| Q1 2026 | 514.58K | $29.90M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
Other funds holding PCVX
- Fidelity Management & Research (FMR) 20.85M sh · $1.21B · Q2 2026
- Janus Henderson Group 16.58M sh · $960.23M · Q1 2026
- BlackRock Inc 12.07M sh · $701.52M · Q2 2026
- Vanguard Group 12.19M sh · $562.63M · Q4 2025
- Wellington Management Group 7.00M sh · $407.00M · Q2 2026
- Geode Capital Management 3.46M sh · $201.13M · Q2 2026
- D. E. Shaw & Co 1.90M sh · $110.56M · Q2 2026
- Maverick Capital 1.61M sh · $93.78M · Q2 2026
- Charles Schwab Investment Management 1.46M sh · $85.15M · Q2 2026
- Northern Trust Corp 1.28M sh · $74.42M · Q2 2026
- Norges Bank Investment Management 1.25M sh · $72.42M · Q2 2026
- JPMorgan Chase & Co 1.23M sh · $71.19M · Q2 2026